15267-98-8

Basic information

• Product Name: Phenol, 4-amino-, monosodium salt
• CAS NO: 15267-98-8
• Molecular Formula: C6H7NO.Na
• Molecular Weight: 131.11
• Mol File: 15267-98-8.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: Phenol, 4-amino-, monosodium salt(CAS DataBase Reference)
• NIST Chemistry Reference: Phenol, 4-amino-, monosodium salt(15267-98-8)
• EPA Substance Registry System: Phenol, 4-amino-, monosodium salt(15267-98-8)

Safety Data

• Hazardous Substances Data: 15267-98-8(Hazardous Substances Data)

Upstream product

• 103-90-2 4-acetaminophenol 
• 6119-34-2 p-aminophenoxyl radical 
• 100-02-7 4-nitro-phenol 
• 123-30-8 4-amino-phenol 
• 824-78-2 4-nitrophenol sodium salt 

Downstream Products

• 426210-16-4 [(CH₂CH₃)4N][W(OC₆H₄-p-NH₂)(S₂C₂(C₆H₄-p-OCH₃)2)2] 
• 426209-80-5 [(CH₂CH₃)4N][W(OC₆H₄-p-NH₂)(S₂C₂(C₆H₄-p-F)2)2] 
• 426209-62-3 [(CH₂CH₃)4N][W(OC₆H₄-p-NH₂)(S₂C₂(C₆H₄-p-Br)2)2] 
• 426210-05-1 [(CH₂CH₃)4N][W(OC₆H₄-p-NH₂)(S₂C₂(C₆H₄-p-CH₃)2)2] 
• 426209-95-2 [(CH₂CH₃)4N][W(OC₆H₄-p-NH₂)(1,2-diphenylethylene-1,2-dithiolate)2] 
• 516526-32-2 4-(7-benzyloxy-6-methoxyquinolin-4-yloxy)aniline 
• 2676-59-7 bis(3,4-diaminophenyl)ether 
• 3070-87-9 N-[4-(4-acetylamino-3-nitrophenoxy)-2-nitrophenyl]acetamide 
• 3070-86-8 N-[4-(4-acetylaminophenoxy)phenyl]acetamide 
• 2687-40-3 4-nitrophenyl 4'-acetamidophenyl ether 
• 2687-41-4 N-[4-(4-aminophenoxy)phenyl]acetamide 
• 3273-78-7 4-(4-amino-3-nitrophenoxy)-2-nitrophenylamine 
• 111963-41-8 para-dimethylphosphinylmethyleneoxyaniline 
• 13522-32-2 N,N-Dimethyl-thiocarbamidsaeure-O-(4-amino-phenylester) 

Relevant articles and documents

Highly porous palladium nanodendrites: Wet-chemical synthesis, electron tomography and catalytic activity

A simple procedure to obtain highly porous hydrophilic palladium nanodendrites in one-step is described. The synthetic strategy is based on the thermal reduction of a Pd precursor in the presence of a positively charged polyelectrolyte such as polyethylenimine (PEI). Advanced electron microscopy techniques combined with X-ray diffraction (XRD), thermogravimetry and BET analysis demonstrate the polycrystalline nature of the nanodendrites as well as their high porosity and active surface area, facilitating a better understanding of their unique morphology. Besides, catalytic studies performed using Raman scattering and UV-Vis spectroscopies revealed that the nanodendrites exhibit a superior performance as recyclable catalysts towards hydrogenation reaction compared to other noble metal nanoparticles.

Photoluminescence as a valuable tool in the optical characterization of acetaminophen and the monitoring of its photodegradation reactions

In this work, new evidence for the photodegradation reactions of acetaminophen (AC) is reported by photoluminescence (PL), Raman scattering and FTIR spectroscopy. Under excitation wavelength of 320 nm, AC shows a PL band in the spectral range of 340–550 nm, whose intensity decreases by exposure to UV light. The chemical interaction of AC with the NaOH solutions, having the concentration ranging between 0.001 and 0.3 M, induces a gradual enhancement of the photoluminescence excitation (PLE) and PL spectra, when the exposure time of samples at the UV light increases until 140 min, as a result of the formation of p-aminophenol and sodium acetate. This behavior is not influenced by the excipients or other active compounds in pharmaceutical products as demonstrated by PLE and PL studies. Experimental arguments for the obtaining of p-aminophenol and sodium acetate, when AC has interacted with NaOH, are shown by Raman scattering and FTIR spectroscopy.

QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF Flt3 AND MEDICINAL COMPOSITIONS CONTAINING THE SAME

An objective of the present invention is to provide compounds and pharmaceticals useful for the treatment of disease where the inhibition of autophosphorylation of FMS-like tyrosine kinase 3(Flt3) is therapeutically effective. The present invention relates to a pharmaceutical composition for use in the treatment or prevention of diseases where the inhibition of autophosphorylation of Flt3 therapeutically or prophylactically effective, which comprises a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein X represents CH or N; Z represents O or S; R1, R2, and R3 represent H, OH, or optionally substituted alkoxy; R4 represents H; R5, R6, R7, and R8 represent H, Hal, alkyl or the like; and R9 represents, e.g., alkyl substituted by t-butyl or the like.